Summary

• INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. INVEGA HAFYERA is not approved for use in patients with dementia-related psychosis.¹
• Clinical studies of INVEGA HAFYERA did not include sufficient numbers of patients ≥65 years to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.¹
• This drug is known to be substantially excreted by the kidney and clearance is decreased in patients with renal impairment. Because elderly patients are more likely to have decreased renal function, INVEGA HAFYERA is not recommended to be used in elderly patients with mild, moderate, or severe renal impairment.¹
• After oral administration of paliperidone in elderly subjects, the C_max and AUC increased 1.2-fold compared to young subjects. This may be attributable to age-related decreases in creatinine clearance.¹

LITERATURE SEARCH

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, and DERWENT Drug File (and/or other resources, including internal/external databases) pertaining to this topic was conducted on 10 May 2024.